MedTrace Logo

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane

NCT01773460 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2016-02-10

No results posted yet for this study

Summary

Everolimus will be given to patients with metastatic breast cancer who already has a progress taking Everolimus but with a change in the endocrine treatment.

Conditions

Interventions

DRUG

Everolimus

Everolimus is given beyond progress (comparison with placebo)

DRUG

Everolimus-placebo

Everolimus-placebo

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • GBG Forschungs GmbH

    lead OTHER

Principal Investigators

  • Sibylle Loibl, Prof. · Krankenhaus Offenbach

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01773460 on ClinicalTrials.gov